Last update 10 Feb 2026

Shanghai Langsheng Biotechnology Co., Ltd.

Subsidiary Company|2020|Shanghai Shi, China

Overview

Basic Info

Introduction
Shanghai Innostellar Biotherapeutics Co.,Ltd. is a high-tech enterprise specializing in the research, development, production and sales of biopharmaceuticals. The company adheres to the concept of "pioneering, innovative and excellent" and has always been committed to the development of safe, efficient and stable biopharmaceutical products.

Tags

Congenital Disorders
Eye Diseases
Other Diseases
AAV based gene therapy
Gene therapy

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
AAV based gene therapy3
Gene therapy1
Top 5 TargetCount
VEGF(Vascular endothelial growth factor)1
RPE65(Retinoid isomerohydrolase)1

Related

4
Drugs associated with Shanghai Langsheng Biotechnology Co., Ltd.
LX-101 (Innostellar)
Target
RPE65
Mechanism
RPE65 gene transference
Active Org.
Innostellar Biotherapeutics Co., Ltd.Ltd. [+1]
Originator Org.
Shanghai Langsheng Biotechnology Co., Ltd.
Active Indication
Biallelic RPE65 mutation associated retinal dystrophy [+1]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
LX102(Innostellar)
Target
VEGF
Mechanism
VEGF modulators
Active Org.
Innostellar Biotherapeutics Co., Ltd.Ltd. [+1]
Originator Org.
Innostellar Biotherapeutics Co., Ltd.Ltd.
Active Indication
Wet age-related macular degeneration
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
LX-107
Target-
Mechanism-
Active Org.
Shanghai Langsheng Biotechnology Co., Ltd.
Originator Org.
Shanghai Langsheng Biotechnology Co., Ltd.
Active Indication
Biallelic RPE65 mutation associated retinal dystrophy [+1]
Inactive Indication-
Drug Highest PhaseEarly Phase 1
First Approval Ctry. / Loc.-
First Approval Date-
9
Clinical Trials associated with Shanghai Langsheng Biotechnology Co., Ltd.
NCT07362927
/ Not yet recruitingEarly Phase 1IIT
An Exploratory Clinical Study Evaluating LX111 Gene Therapy in Patients With Diabetic Macular Edema (DME)
NCT07317934
/ Not yet recruitingPhase 3
A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial
ChiCTR2500115643
/ RecruitingPhase 3IIT
A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants with Neovascular Age-Related Macular Degeneration – The STELLAR Trial
100 Clinical Results associated with Shanghai Langsheng Biotechnology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Shanghai Langsheng Biotechnology Co., Ltd.
Login to view more data
100 Deals associated with Shanghai Langsheng Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Langsheng Biotechnology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Early Phase 1
2
2
Phase 3
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free